Alaunos Net Tangible Assets from 2010 to 2026
| TCRT Stock | USD 2.56 0.01 0.39% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 44.3 M | Current Value 55.8 M | Quarterly Volatility 85.6 M |
Check Alaunos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alaunos Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.2 K, Selling And Marketing Expenses of 4.1 M or Total Revenue of 8.6 K, as well as many indicators such as Price To Sales Ratio of 261, Dividend Yield of 0.0294 or PTB Ratio of 1.4. Alaunos financial statements analysis is a perfect complement when working with Alaunos Therapeutics Valuation or Volatility modules.
Alaunos | Net Tangible Assets | Build AI portfolio with Alaunos Stock |
The evolution of Net Tangible Assets for Alaunos Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Alaunos Therapeutics compares to historical norms and industry peers.
Latest Alaunos Therapeutics' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Alaunos Therapeutics over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Alaunos Therapeutics' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alaunos Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Alaunos Net Tangible Assets Regression Statistics
| Arithmetic Mean | (11,531,297) | |
| Geometric Mean | 74,293,303 | |
| Coefficient Of Variation | (742.65) | |
| Mean Deviation | 80,258,544 | |
| Median | 38,555,000 | |
| Standard Deviation | 85,637,284 | |
| Sample Variance | 7333.7T | |
| Range | 220.8M | |
| R-Value | 0.77 | |
| Mean Square Error | 3168T | |
| R-Squared | 0.60 | |
| Significance | 0.0003 | |
| Slope | 13,081,498 | |
| Total Sum of Squares | 117339.9T |
Alaunos Net Tangible Assets History
About Alaunos Therapeutics Financial Statements
Alaunos Therapeutics shareholders use historical fundamental indicators, such as Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Alaunos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Alaunos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Alaunos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 44.3 M | 55.8 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Alaunos Stock Analysis
When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.